Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:9/1/2015)... , ... September 01, 2015 , ... Routines… every family ... routines can help make things easier for parents, caregivers and children too. Here are ... transitions both big and small become more fluid. When a routine is implemented into ...
(Date:9/1/2015)... ... 01, 2015 , ... The premier online medical education company ... leader in podiatric, surgical and wound care conferences . The Residency Education ... speakers at the podium and across the table during hands-on surgical and advanced ...
(Date:8/31/2015)... ... 31, 2015 , ... Jvion, the Atlanta-based leader in predictive ... focused on helping hospital perform under the Center for Medicare & Medicaid Services’ ... based on performance across four domains related to care quality. To receive a ...
(Date:8/31/2015)... Beach, FL (PRWEB) , ... August 31, 2015 , ... ... of companies – has teamed up with fellow South Walton property management ... on eliminating extreme poverty in remote parts of the world. The two companies will ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... The ... that Firm Partner William Scott has been nominated by his peers to earn a ... less than five percent of attorneys in the state of Illinois. The nomination process ...
Breaking Medicine News(10 mins):Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2
... Oct. 31 The Ensign,Group, Inc. (Nasdaq: ... group of,skilled nursing, rehabilitative care services and assisted ... the Oppenheimer &,Co. 19th Annual Healthcare Conference on ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Christopher Christensen, the company,s ...
... October 31, 2008 A study by ... was very useful in the diagnosis of obscure gastrointestinal ... majority of patients. The study appears in the October ... peer-reviewed scientific journal of the American Society for Gastrointestinal ...
... Data Demonstrate High, Durable Response Rates for Patients with ... ... Oct. 31 Cephalon, Inc., (Nasdaq:,CEPH) today announced that ... (bendamustine hydrochloride) for Injection for the,treatment of patients with ...
... Million Election Day Bond Referendum to,Support Water, Sewage ... Edward G.,Rendell pointed to a report issued today ... water and sewer infrastructure and,warns of an impending ... funds these systems., The report, compiled by ...
... savings ends Sunday,morning, roads may become more dangerous, says ... free driver safety films and,programs for schools and other ... weekend, the drive home from work or,school for many ... of The,National Road Safety Foundation. "The time change and ...
... 31 The Aurora Visiting Nurse,Association honored donors, ... Wisconsin during the home health and hospice agency,s ... Hospital of Wisconsin was recognized as corporate friend ... pediatric program., "The relationship between Aurora VNA ...
Cached Medicine News:Health News:The Ensign Group to Present at the Oppenheimer 19th Annual Healthcare Conference 2Health News:Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding 2Health News:Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding 3Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Health News:Governor's Task Force Cites PA's $36.5 Billion Water Infrastructure Need; Report Underscores Call for Additional Investments 2Health News:Governor's Task Force Cites PA's $36.5 Billion Water Infrastructure Need; Report Underscores Call for Additional Investments 3Health News:Turning Clocks Back Increases Risk of Drowsy Driving 2Health News:Aurora Visiting Nurse Association of Wisconsin Honors Supporters, Volunteers 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: